Do you have extra, unwanted fullness beneath your chin? Kybella® is the only FDA-approved injectable treatment that destroys fat cells under the chin.

Submental fullness, sometimes referred to as ‘double chin’, affect both men and women and can be caused by weight gain, age, or genetics. Whether it is something you have had your entire life, developed over the years, or something you have noticed recently, Kybella® works to reduce the fullness under the chin in just 15-20 minutes. Kybella® at Solimar MediSpa is administered by our experienced physician and is tailored to every patient. This treatment will leave you feeling more confident from all angles. 


Kybella Before & After

Destroy Fat Cells Under the Chin


The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, KYBELLA® destroys fat cells, resulting in a noticeable reduction in fullness under the chin. Once destroyed, these cells can no longer store or accumulate fat, so further treatment is not expected once you reach your desired aesthetic goal.

INDICATION KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
CONTRAINDICTIONS KYBELLA® is contraindicated in the presence of infection at the injection sites.
Marginal Mandibular Nerve Injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. Dysphagia Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition. Injection-Site Hematoma/Bruising In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.